Health Situation reports provide an update on the epidemiological situation and actions taken by the Ministry of Health and partners. These are issued regularly, and may be more frequent when there are rapid changes in the situation.
So far, 64,000 doses of COVID-19 vaccines have been received in Vanuatu, comprising 24,000 AstraZeneca doses through COVAX Facility, 20,000 Sinopharm doses received from the Chinese Government and 20,000 AstraZeneca doses received from the Australian Government.
Vaccine roll-out started on 2 June 2021 with vaccines prioritised to health workers, front line workers (e.g. border workers, quarantine facility staff, public transport drivers), the elderly (55 and over), and people 35 and over with existing medical conditions.
Up until 1 August 2021, there were 27,716 COVID-19 doses administered in Vanuatu. A total of 27,592 people received at least one dose of AstraZeneca or Sinopharm, including 653 healthcare workers, 1,251 other frontline workers, 5,358 elderly persons and 3,988 persons with known underlying conditions. 121 people have received two doses of Sinopharm and 15 have received two doses of AstraZeneca, and are considered fully vaccinated.
There have been 145 adverse events following COVID-19 immunization notified in Vanuatu. Of these 8 have been serious and have required investigation, 6 have required causality assessments with 3 confirmed to be coincidental or immunization anxiety-related and not related to the COVID-19 vaccine product or immunization error. Results from 2 events are pending but evidence indicates no Thrombosis (blood clots) with Thrombocytopenia Syndrome (TTS).
Vanuatu remains in Scenario 1. There are currently no COVID-19 cases in isolation or quarantine, with no evidence of local transmission in Vanuatu since the beginning of the pandemic.
Updates will be communicated via the COVID-19 website: www.covid19.gov.vu